Streptokinase-induced activation of the kallikrein-kinin system and of the contact phase in patients with acute myocardial infarction

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 5, 1998, Pages 764-772

  Hoffmeister, Hans Martin ^a   Ruf, Monika ^a   Wendel, Hans Peter ^b   Heller, Wolfgang ^b   Seipel, Ludger ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Acute myocardial infarction; Bradykinin generation; Contact phase; Kallikrein kinin system; Streptokinase

Indexed keywords

ANTIPLASMIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 12; BRADYKININ; CALCIUM CHANNEL BLOCKING AGENT; CHROMOGENIC SUBSTRATE; COMPLEMENT COMPONENT C1S INHIBITOR; CREATINE KINASE; HEPARIN; HIGH MOLECULAR WEIGHT KININOGEN; KALLIKREIN; KININ; NITRATE; PLASMINOGEN; STREPTOKINASE; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FIBRINOLYTIC THERAPY; HEMOSTASIS; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KALLIKREIN KININ SYSTEM; MALE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ACUTE DISEASE; AGED; ANALYSIS OF VARIANCE; FACTOR XII; FEMALE; FIBRIN; HUMANS; KALLIKREIN-KININ SYSTEM; KALLIKREINS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; STREPTOKINASE; THROMBIN;

EID: 0031957546     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199805000-00016     Document Type: Article

References (41)

1. Grines CL, Browne KF, Marco J, et al. Comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction: the primary angioplasty in myocardial infarction study group. N Engl J Med 1993;328:673-9.
2. Eisenberg PR, Sherman LA, Perez J, Jaffe AS. Relationship between elevated plasma levels of cross-linked fibrin degradation products (XL-FDP) and the clinical presentation of patients with myocardial infarction. Thromb Res 1987;46:109-20.
3. Rapold HJ. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation. Lancet 1990;1:481-2.
4. Gulba DC, Westhoff-Bleck M, Jost S, et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Circulation 1991;82:937-44.
5. Hoffmeister HM, Jur M, Wendel HP, Heller W, Seipel L. Alterations of the coagulation, the fibrinolytic and the kallikrein-kinin system in the acute and post-acute phase in patients with unstable angina pectoris. Circulation 1995;91:2520-7.
6. Hoffmeister HM, Jur M, Ruf M, Heller W, Seipel L. Inhibitors of the hemostasis and related systems in patients with acute myocardial infarction or unstable angina pectoris. Fibrinolysis 1995;9:104-8.
7. Huber K, Rose D, Resch I. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromh Haemost 1988;60:372-6.
8. Gram J, Kluft C, Jespersen J. Depression of tissue plasminogen activator (t-PA) activity and rise of t-PA inhibition and acute phase reactants in blood of patients with acute myocardial infarction (AMI). Thromb Haemost 1987;58:817-21.
9. Hoffmeister HM, Beyer ME, Engel Z, Heller W. Activation of leukocytes and of the kallikrein-kinin system in patients with unstable angina pectoris. Clin Cardiol 1994;17:27-30.
10. Zalweski A, Shi Y, Nardone D, et al. Evidence for reduced fibrinolytic activity in unstable angina at rest. Circulation 1991;83:1685-91.
11. Gotoh K, Minamino T, Katoh O, et al. The role of intracoronary thrombus in unstable angina: angiographic assessment and thrombolytic therapy during ongoing anginal attacks. Circulation 1988;77:526-34.
12. Ewald GA, Eisenberg PR. Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation 1995;91:28-36.
13. Gallimore MJ, Friberger P. Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein like activity in human plasma. Thromb Res 1982;25:293-8.
14. Gallimore MJ, Rees WA, Fuhrer G, Heller W. A direct chromogenic peptide substrate assay for Hageman factor (FXII). Fibrinolysis 1987;1:12-7.
15. 1-esterase inhibitor activity in plasma. Clin Chem Acta 1983;128:359-66.
16. 1-inactivator-resistant fibrinolytic activity in plasma euglobulin fractions: its relation to vascular activator in blood and its role in euglobulin fibrinolysis. Thromb Res 1978;13:135-51.
17. Elms MJ, Bunce IH, Gundesen PG, et al. Measurement of cross-linked fibrin degradation products - an immunoassay using monoclonal antibodies. Thromb Haemost 1983;50:591-4.
18. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988;59:101-6.
19. Gallimore MJ. Plasma-Präkallikrein. Hämostaseologie 1987;7: 166-71.
20. Lucore CL, Sobel BE. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation 1988;77:660-9.
21. Munkvad S, Jespersen J, Gram J, Kluft C. Depression of factor-XII-dependent fibrinolytic activity characterizes patients with early myocardial reinfarction after recombinant tissue-type plasminogen activator therapy. J Am Coll Cardiol 1991;18:454-8.
22. Kaplan AP, Austen KF. A prealbumin activator of prekallikrein. J Exp Med 1971;133:696-712.
23. Griffin JH. Role of surface in surface-dependent activation of Hageman factor. Proc Natl Acad Sci U S A 1978;75:1998-2002.
24. Goto S, Kawai Y, Abe S, et al. Serial changes in coagulant activities after thrombolytic therapy for acute myocardial infarction. Angiology 1994;45:273-84.
25. Rennie JA, Ogston D. Changes in coagulation factors following acute myocardial infarction in man. Haemostasis 1976;5:258-64.
26. Gidron E, Margalit R, Oliven A, Shalitin Y. Effect of myocardial infarction on components of fibrinolytic system. Br Heart J 1977;39:19-24.
27. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardial 1990;65:168-72.
28. Kruskal JB, Commerford PJ, Franks JJ, Kirsch RE. Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 1987;317:1361-5.
29. Marder VJ. What does the "dimer test" test? Circulation 1990;82:1514-5.
30. Munkvad S, Gram J, Jespersen J. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heart J 1990;11:525-8.
31. ECAT Angina Pectoris Study Group. ECAT Angina Pectoris Study: baseline associations of haemostatic factor with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993;14:8-17.
32. Hamsten A, Walldius G, Szamosi A, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
33. Wiman B, Hamsten A. Correlations between fibrinolytic function and acute myocardial infarction. Am J Cardiol 1990;66:54-6G.
34. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989;79:101-6.
35. Pixley RA, Cassello A, De La Cadena RA, Kaufman N, Colman RW. Effect of heparin on the activation of factor XII and the contact system in plasma. Thromb Haemost 1991;66:540-7.
36. Heller W, Fuhrer G, Gallimore MJ, Hoffmeister HE. Prekallikrein and kallikrein-like activity determination in heparinized plasma samples. Haemostasis 1985;15:64-5.
37. Eisenberg PR, Miletich JP, Sobel BE. Factors responsible for the differential procoagulant effects of diverse plasminogen activators in plasma. Fibrinolysis 1991;5:217-24.
38. Eisenberg PR, Miletich JP. Induction of marked thrombin activity in anticoagulated whole blood. Thromb Res 1989;55:635-43.
39. Gemmill J, Hogg K, Douglas J, et al. The incidence and mechanism of hypotension following thrombolytic therapy for acute myocardial infarction with streptokinase-containing agents: lack of relationship to pretreatment streptokinase resistance. Eur Heart J 1993;14:819-25.
40. Agostoni A, Gardinali M, Frangi D, et al. Activation of complement and kinin-systems after thrombolytic therapy in patients with acute myocardial infarction. Circulation 1994;90:2666-70.
41. Linz W, Martorana PA, Schölkens BA. Local inhibition of bradykinin degradation in ischemic hearts. J Cardiovasc Pharmacol 1990;15:99-109.